PanChol (live attenuated oral cholera vaccine) / Brigham and Womens Hospital - LARVOL DELTA

Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial. (PubMed, Lancet Infect Dis) - P1 | "A single oral dose of PanChol was safe and well tolerated at all doses and induced 100% vibriocidal seroconversion over a 100 000-fold dose range. These findings support the progression of PanChol into later phase clinical trials, including studies in endemic settings and in children."

First-in-human • Journal • Cholera • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Going for three: what is the role for triplex testing for HSV-1, HSV-2, and VZV? (PubMed, ASM Case Rep) - "A recent study by B. W. Buchan and P. Pancholi published in ASM Case Reports (2:e00112-25, 2025, https://doi.org/10.1128/asmcr.00112-25) highlights the limitations of this approach, revealing a substantial number of cases where provider-ordered testing missed the causative virus...In some cases, clinical diagnosis may be insufficient for differentiation among HSV-1, HSV-2, and VZV. More studies are needed to help identify use cases where triplex testing is most appropriate, but broader availability and implementation of triplex NAATs have the potential to promote better patient management and infection prevention practices."

Journal • Herpes Simplex • Herpes Zoster • Infectious Disease • Varicella Zoster

Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Centre for Infectious Disease Research in Zambia

New P1 trial • Cholera

PanChol: A Dual Acting Oral Cholera Vaccine Candidate (ASM Microbe 2025) - "The observed rapid protection is partly based on PanChol-mediated colonization resistance resulting in lower colonization of the challenge strain. Currently, we are characterizing the underlying host and bacterial factors that account for this rapid protective effect of PanChol in the murine model."

Cholera

PanChol: A Dual Acting Oral Cholera Vaccine Candidate (ASM Microbe 2025) - "The observed rapid protection is partly based on PanChol-mediated colonization resistance resulting in lower colonization of the challenge strain. Currently, we are characterizing the underlying host and bacterial factors that account for this rapid protective effect of PanChol in the murine model."

Cholera

Results of the Phase 1 Trial of PanChol, a rapid-acting live attenuated Oral Cholera Vaccine (ASTMH 2024) - No abstract available

P1 data • Cholera

94 - Solving the Supply Shortage: Present and Future Prospects for Cholera Vaccines (ASTMH 2024) - "Additional presentations will include the Phase 1 trial results of PanChol a genetically engineered rapid-acting live attenuated Oral Cholera Vaccine, and the Phase 1 trial results of a Cholera Conjugate Vaccine (CCV) based on the immunodominant protective antigen of cholera, the O-specific polysaccharide (OSP) component of LPS, linked to a carrier protein to generate T cell dependent responses...Finally, the development plan of a novel oral capsule vaccine, DuoChol, that combines inactivated whole cell bacteria and recombinant cholera toxin B will be presented including the results of country workshops in South Asia and Sub-Saharan Africa to assess feasibility, cost and policy implications of a capsule vaccine. This highly thermostable and light weight vaccine is expected to have efficacy similar to Dukoral but significantly reduce delivery costs and challenges. A phase 1 trial is expected in early 2025."

Cholera

COLECTOMY INDICATIONS DURING ULCERATIVE COLITIS : A TWENTY-YEAR RETROSPECTIVE FROM A UNIVERSITY HOSPITAL CENTER (UEGW 2024) - "The majority were pancholic and 35% were left-handed. The study confirms changes in colectomy criteria for chronic ulcerative colitis over the past two decades, with a decrease in treatment-resistant cases and an increase in severe acute colitis or dysplasia/cancer cases, while laparoscopy usage has increased, reducing morbidity despite biotherapies usage."

Retrospective data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Oncology • Ulcerative Colitis

"Still waiting @yyCBEdu @AlbertaEd cc @LauraHack34 @danacaresyyc @FreshAirAB @CanPaedSociety @CAPE_ACME @AdrianaLaGrange @demetriosnAB @pancholi_rakhi @luanne_metz #IAQ" (@ClaireKraatz)

"@A_R_TforPEACE @RahulBanerjeeMD @pancholi_rakhi @Z_u_l_u_i_n_k @sweetirish01" (@BruceRawji)

"@JanisIrwin, @DanielleLarivee, @luanne_metz, @GandalfIf, @pancholi_rakhi, @SPhillipsAB, @MarieFrRenaud, @chantal_SMC, @KarenShaw_, @LoriSigurdson, @heathersweetab, @lizettendp, @JTweedleRD, @PeggyBevClare …3/3" (@LisboaYYC)

"@AACR blog (12/8): "The Fungi Within Us: The Mycobiome’s Emerging Role in Cancer" by Neha J. Pancholi, PhD https://t.co/TFqGWcBnVN" (@GMaPR1N)

Oncology